Brokerages expect Pharmerica Corporation (NYSE:PMC) to post $592.15 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Pharmerica Corporation’s earnings, with the highest sales estimate coming in at $595.00 million and the lowest estimate coming in at $589.30 million. Pharmerica Corporation posted sales of $519.60 million during the same quarter last year, which suggests a positive year-over-year growth rate of 14%. The company is scheduled to announce its next earnings report before the market opens on Friday, August 4th.
According to Zacks, analysts expect that Pharmerica Corporation will report full year sales of $592.15 million for the current financial year. For the next financial year, analysts expect that the business will report sales of $2.59 billion per share, with estimates ranging from $2.55 billion to $2.64 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Pharmerica Corporation.
Pharmerica Corporation (NYSE:PMC) last announced its quarterly earnings results on Wednesday, May 10th. The company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.02. The company had revenue of $566.80 million during the quarter, compared to the consensus estimate of $536.85 million. Pharmerica Corporation had a net margin of 0.98% and a return on equity of 11.03%. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 earnings per share.
A number of research firms recently commented on PMC. Zacks Investment Research raised shares of Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Saturday, June 24th. ValuEngine cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, BidaskClub cut shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research report on Monday.
ILLEGAL ACTIVITY NOTICE: This piece was published by Rincon Hill News and is owned by of Rincon Hill News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://rinconhillneighbors.org/2017/08/19/pharmerica-corporation-nysepmc-expected-to-post-quarterly-sales-of-592-15-million-updated-updated.html.
Shares of Pharmerica Corporation (NYSE:PMC) traded down 0.40% during midday trading on Friday, hitting $25.05. 187,459 shares of the company traded hands. Pharmerica Corporation has a 52 week low of $19.20 and a 52 week high of $28.72. The stock has a market capitalization of $778.93 million, a P/E ratio of 34.79 and a beta of 0.93. The company has a 50-day moving average price of $25.85 and a 200-day moving average price of $24.73.
Several hedge funds and other institutional investors have recently bought and sold shares of PMC. Louisiana State Employees Retirement System boosted its position in Pharmerica Corporation by 0.8% in the first quarter. Louisiana State Employees Retirement System now owns 12,500 shares of the company’s stock worth $293,000 after buying an additional 100 shares in the last quarter. Capstone Asset Management Co. boosted its position in Pharmerica Corporation by 0.9% in the second quarter. Capstone Asset Management Co. now owns 16,041 shares of the company’s stock worth $421,000 after buying an additional 150 shares in the last quarter. Arizona State Retirement System boosted its position in Pharmerica Corporation by 1.3% in the first quarter. Arizona State Retirement System now owns 16,016 shares of the company’s stock worth $375,000 after buying an additional 200 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in Pharmerica Corporation by 4.7% in the first quarter. Tudor Investment Corp ET AL now owns 8,602 shares of the company’s stock worth $201,000 after buying an additional 389 shares in the last quarter. Finally, Texas Permanent School Fund boosted its position in Pharmerica Corporation by 1.8% in the second quarter. Texas Permanent School Fund now owns 22,703 shares of the company’s stock worth $596,000 after buying an additional 411 shares in the last quarter. 92.75% of the stock is owned by institutional investors and hedge funds.
Pharmerica Corporation Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with our FREE daily email newsletter.